ⓘ This article is third-party content and does not represent the views of this site. We make no guarantees regarding its accuracy or completeness.
BioVie Inc. (NASDAQ: BIVI) is the focus on IBN’s latest stock spotlight. The company’s shares have moved -3.89% on the day to $10.12.
BioVie Inc., a clinical stage biotechnology company, engages in the discovery, development, and commercialization of drugs therapies in the United States. Its products in pipeline include BIV201, which completed Phase IIa clinical trial for the treatment of ascites due to chronic liver cirrhosis; and NE3107, which is in Phase III clinical trial for the treatment of patients with mild to moderate Alzheimer’s disease and Phase I clinical trial for the treatment of Parkinson’s disease.
So far today, approximately 165.27k shares of BioVie Inc. have been exchanged, as compared to an average 30-day volume of 575.52k shares.
BioVie Inc. share prices have moved between a 52-week high of $14.38 and a 52-week low of $1.32. The stock has moved 29.2% over the past week.
IBN consists of financial brands introduced to the investment public over the course of 17+ years. With IBN, we have amassed a collective audience of millions of social media followers. These distinctive investor brands aim to fulfill the unique needs of a growing base of client-partners. IBN will continue to expand our branded network of highly influential properties, leveraging the knowledge and energy of specialized teams of experts to serve our increasingly diversified list of clients.
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer
Report this content
If you believe this article contains misleading, harmful, or spam content, please let us know.
